Ireland is using a high-profile research mission to Massachusetts to strengthen its position in pharmaceutical innovation, bringing researchers and industry representatives closer to international partners who can help translate scientific discoveries into new medicines and commercial opportunities.

Led by Minister for Further and Higher Education, Research, Innovation and Science James Lawless, the delegation includes Research Ireland CEO Diarmuid O’Brien and representatives from seven research centres and commercialisation hubs. As reported by The Irish Post, planned engagements include MIT, the University of Massachusetts, IBM and Boston Scientific. The Department of Further and Higher Education has also identified cancer treatments, advanced therapies and medical devices among the research areas being showcased.

The mission builds on the Government’s €460 million Rinn research network, officially announced by Research Ireland in June 2026. The seven centres cover advanced therapies, pharma and biopharma, medical devices and four other strategic research fields. Research Ireland’s announcement confirms that the network brings together 17 research-performing organisations, supports 577 research positions and aims to develop more than 800 PhD researchers over eight years.

For pharmaceutical businesses, two areas of the programme stand out. Rinn Pharma & Biopharma has received €60.3 million to support research and innovation in medicines, while Rinn Advanced Therapies has been allocated approximately €51.1 million for personalised immune cell therapeutics. These investments create a substantial research base for work spanning drug development, advanced treatments and the technologies needed to support future healthcare innovation.

The National Institute for Bioprocessing Research and Training (NIBRT) is contributing expertise across three Rinn centres, with capabilities spanning cell and gene therapies, biologics, RNA medicines and biomanufacturing. Its announcement on the Rinn programme identifies more than €175 million in strategic research investment across the advanced therapies, pharmaceutical and medical-device centres. This links discovery research with the development and manufacturing expertise needed to progress emerging medicines.

The commercial opportunity extends beyond the research institutions themselves. IDA Ireland’s overview of Rinn highlights the network’s role in making Ireland’s research capabilities more accessible to industry, supporting collaboration between multinational companies, SMEs and academic partners. The Massachusetts mission provides another opportunity to develop those connections internationally.

For the sector, the lesson is direct: Ireland’s investment in pharmaceutical research gains greater significance when it is connected to global expertise and commercial partnerships. By showcasing its capabilities in drug development, biopharma and advanced therapies, the country can strengthen the links between research, manufacturing and the next generation of medicines.